Data on surrogate end points such as blood pressure or body weight have
often been used to support the approval of new pharmacologic treatments for
cardiovascular risk factors. In small, short-term studies, a new drug reduces
the level of a risk factor, and the changes in risk factor levels are interpreted
as if the health benefits expected on the basis of those changes will necessarily
follow. An editorial on the pharmacotherapy of obesity illustrates the argument1: in the context of discussing the association between
appetite suppressant drugs and primary pulmonary hypertension,2
the editorialists used observational evidence on the association of body mass
index with mortality and translated data on weight loss in a small, short-term
trial of dexfenfluramine3 into an estimate
of lives that could be saved by long-term drug therapy for obesity. The US
Food and Drug Administration (FDA) approved dexfenfluramine on the basis of
this same surrogate end point argument4: "the
potential health benefits of anorectic drugs outweigh their risk when considered
against the health hazards of obesity."5 When,
after the drug was approved, the adverse effects were found to be greater
than estimated on the basis of preapproval trials,6,7
the drug was withdrawn. Is this an example of the drug-approval process working
well, or does it point to a fundamental flaw in the way drugs are approved?
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 96
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.